On 17 January 2018, orphan designation (EU/3/17/1959) was granted by the European Commission to GW Research Ltd, United Kingdom, for cannabidiol for the treatment of tuberous sclerosis.
The sponsorship was transferred to GW Pharma (International) B.V., the Netherlands, in April 2019.
Cannabidiol for treatment of tuberous sclerosis has been authorised in the EU as Epidyolex since 16 April 2021.
Treatment of tuberous sclerosis
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.